D. Assouline

发表

Cardiac dysfunction in clinical trials of trastuzumab.

D. Fric, D. Coeffic, P. Winckel, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer following Hodgkin′s disease: A case‐control study

N. Day, J. Kaldor, P. Band, 1992, International journal of cancer.

Analysis and classification of interval cancers in a French breast cancer screening programme (département of Isère).

M. Bolla, F. Ménégoz, C. Exbrayat, 1999, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Leukemia following Hodgkin's disease.

N. Day, J. Cuzick, J. Kaldor, 1990, The New England journal of medicine.

Hodgkin's disease after transplantation.

G. Delsol, Y. Lebranchu, A. Moreau, 1996, Transplantation.

Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS.

R. Houot, L. Fornecker, R. Gressin, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum interleukin-6 levels in adult acute myelogenous leukemia: relationship with disease characteristics and outcome.

X. Thomas, E. Archimbaud, M. Joly, 1997, Leukemia & lymphoma.

Sequential Chemotherapy with Mitoxantrone, Etoposide and Cytarabine for Previously Treated Acute Myeloid Leukemia: EMA 86 Regimen

P. Fenaux, X. Thomas, X. Troussard, 1996 .

C. Leyronnas, B. Aguilaniu, D. Fric, 2006, Annals of Hematology.

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.

V. Diehl, R. Fisher, D. Crowther, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognosis of patients with advanced hodgkin's disease

F. Berger, É. Lepage, P. Lederlin, 1997, Cancer.

Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens.

I. Ray-Coquard, T. Bachelot, E. Pujade-Lauraine, 2003, Gynecologic oncology.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

H. Blanché, M. Mathieu, H. Bonnefoi, 2017, npj Breast Cancer.

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

G. Thomas, D. Cox, H. Blanché, 2016, Breast Cancer Research.

Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study

A. Monnier, J. Douillard, X. Sun, 2001, British Journal of Cancer.

Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study.

E. Wattel, X. Thomas, E. Archimbaud, 1999, Leukemia & lymphoma.

Massive mediastinal extramedullary hematopoiesis in hereditary spherocytosis: A case report

B. Coiffier, P. Felman, D. Espinouse, 1990, American journal of hematology.

TICLOPIDINE AND APLASTIC ANAEMIA

M. Ffrench, A. Khelif, D. Assouline, 1993, British journal of haematology.

Successful systemic thrombolysis of hepatic vein thrombosis in a patient with promyelocytic leukemia treated with all‐trans retinoic acid

E. Archimbaud, C. Négrier, D. Bodnar, 1995, American journal of hematology.

Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia

C Sebban, A Gafni, A. Gafni, 1995, American journal of hematology.

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients

G. Thomas, D. Cox, H. Blanché, 2016, Oncotarget.

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort

G. Thomas, D. Cox, H. Blanché, 2017, npj Breast Cancer.

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

J. Armitage, V. Diehl, T. Lister, 1998, The New England journal of medicine.

Topotecan and paclitaxel in second line treatment of advanced ovarian cancer (AOC): a gineco phase II trial

E. Pujade-Lauraine, M. Fabbro, B. Leduc, 2001 .

Phase II study with Taxol® (paclitaxel) and Gemzar® (gemcitabine) in metastatic non-small cell lung cancer (NSCLC)

A. Monnier, J. Douillard, X. Sun, 2000 .

Interim Results of the RiPAD+C Regimen Including Velcade in Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group.

R. Gressin, O. Tournilhac, Sophie Park, 2008 .

R. Houot, L. Fornecker, R. Gressin, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis of patients with advanced hodgkin's disease

F. Berger, É. Lepage, P. Lederlin, 1997, Cancer.